Biotech Archives | the deep dive

A Heart Disease Cure For Pericarditis? Phase 3 Trial Advances | David Elsley – Cardiol Therapeutics

April 26, 2025 11:38 AMApril 25, 2025 2:26 PM JP Alegre 0 Comments Cardiol Therapeutics, David Elsley, The Daily Dive

Discover the major breakthrough at Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) as CEO David Elsley reveals the enrollment of their first patient in the pivotal Phase 3 MAVERIC trial for recurrent pericarditis. In this concise interview, Elsley discusses how their oral drug therapy aims to prevent new episodes of this debilitating heart condition, the impressive Phase 2 results showing significant pain reduction, and the potential timeline for market entry by mid-2026.

Biotech Latest News

Cardiol Sees First Patient Enrolled Under Phase III MAVERIC Clinical Trial

April 17, 2025 7:59 AMApril 17, 2025 7:59 AM Jay Lutz 0 Comments

Cardiol Therapeutics (TSX: CRDL) has reached a major milestone with the announcement that the first patients have been enrolled into a phase III clinical trial for its lead drug candidate, CardiolRx™.

Biotech Latest News

Cytophage Launches Trials For OvaPhage Under Hatchery Partnership

February 6, 2025 7:29 AMFebruary 5, 2025 11:10 PM Jay Lutz 0 Comments Cytophage Technologies

Cytophage Technologies (TSXV: CYTO) has officially launched trials with one of the largest poultry hatcheries in Canada. The trial will see Cytophage’s OvaPhage product used to target harmful bacteria on the surface of eggs.

Biotech Latest

Novo Nordisk Shares Surge After Next-Gen Obesity Drug Shows 22% Weight Loss

January 26, 2025 9:16 AMJanuary 25, 2025 10:57 PM ER Velasco 0 Comments Novo Nordisk, obesity

Novo Nordisk witnessed a significant uptick in its share price during European trading on Friday following the announcement of promising

Biotech Latest

MustGrow Acquires NexusBioAg For $1.66 Million In Cash, Future Earn-Out Payments

January 2, 2025 8:29 AMJanuary 2, 2025 8:29 AM Jay Lutz 0 Comments MustGrow Biologics

MustGrow Biologics (TSXV: MGRO) has completed the previously announced acquisition of NexusBioAg from Univar Solutions Canada. Classified as an asset

Biotech Latest News

Cardiol Therapeutics Sees Insider Buying From Leadership Team And Board Members

December 27, 2024 9:52 AMDecember 27, 2024 9:44 AM Jay Lutz 0 Comments Cardiol Therapeutics

Cardiol Therapeutics (TSX: CRDL) has seen a series of insider buys made in recent days, which follows the company seeing success under phase two trials announced in November. A total of four insiders have been in the market this week buying shares, including the firms chief executive, as well as its chief financial officer.

Biotech Latest News

Cytophage Enters Partnership To Launch Phage Clinical Treatment Program In Manitoba

December 12, 2024 5:14 PMDecember 12, 2024 4:33 PM Jay Lutz 0 Comments Cytophage Technologies

Cytophage Technologies (TSXV: CYTO) announced a landmark agreement this morning that will see the establishment of Manitoba’s first Phage Clinical Treatment Program. The program will aim to offer new options for patients to manage antibiotic-resistant infections.

Biotech Latest

Cassava Sciences Stock Plummets Amid Trial Failure and Shkreli’s Takedown

November 26, 2024 11:40 AMNovember 26, 2024 10:54 AM ER Velasco 0 Comments Cassava Sciences

Cassava Sciences, Inc. (NASDAQ: SAVA) witnessed a dramatic over 85% plunge in its stock price following the release of disappointing

Biotech Latest Video Series

Game-Changing Solution for Heart Inflammation? | David Elsley – Cardiol Therapeutics

November 24, 2024 11:48 AMNovember 23, 2024 9:49 PM Jay Lutz 0 Comments Cardiol Therapeutics, David Elsley

In this interview with David Elsley, President and CEO of Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL), we explore the company’s innovative approach to treating inflammatory heart conditions.

Biotech Latest News

Cardiol To Advance CardiolRx To Phase III Trial Following Positive Results

November 19, 2024 8:19 AMNovember 19, 2024 8:10 AM Jay Lutz 0 Comments Cardiol Therapeutics

Cardiol Therapeutics (TSX: CRDL) has seen success under a phase II trial conducted on CardiolRx, which is the company’s lead small molecule drug candidate. The drug is currently going through clinical trials for use in the treatment of heart disease, specifically recurrent pericarditis and acute myocarditis.

← Previous